Each year, respiratory syncytial virus (RSV) hospitalizes an estimated 60,000-160,000 older US adults. After decades of development, the FDA approved two vaccines for older adults. In this faculty Q&A, Dave Hutton, a U-M professor of Health Management and Policy and Global Public Health, explores the potential cost-effectiveness of these vaccines.
